UniProtKB/Swiss-Prot P15088 : Variant p.Thr171Met
Mast cell carboxypeptidase A
Gene: CPA3
Feedback ?
Variant information
Variant position:
171
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LB/B
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Threonine (T) to Methionine (M) at position 171 (T171M, p.Thr171Met).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from medium size and polar (T) to medium size and hydrophobic (M)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
171
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
417
The length of the canonical sequence.
Location on the sequence:
DNPLYVLKIGEKNERRKAIF
T DCGIHAREWVSPAFCQWFVY
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human DNPLYVLKIGEKNERRKAIFT DCGIHAREWVSPAFCQWFVY
Mouse DNPLYVLKIGKKDGERKAIFM DCGIHAREWISPAFCQWFVY
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Literature citations
Cloning of cDNAs that encode human mast cell carboxypeptidase A, and comparison of the protein with mouse mast cell carboxypeptidase A and rat pancreatic carboxypeptidases.
Reynolds D.S.; Gurley D.S.; Stevens R.L.; Sugarbaker D.J.; Austen K.F.; Serafin W.E.;
Proc. Natl. Acad. Sci. U.S.A. 86:9480-9484(1989)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANT MET-171;
Cloning and characterization of the novel gene for mast cell carboxypeptidase A.
Reynolds D.S.; Gurley D.S.; Austen K.F.;
J. Clin. Invest. 89:273-282(1992)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANT MET-171;
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANT MET-171;
Human skin mast cell carboxypeptidase: functional characterization, cDNA cloning, and genealogy.
Natsuaki M.; Stewart C.B.; Vanderslice P.; Schwartz L.B.; Natsuaki M.; Wintroub B.U.; Rutter W.J.; Goldstein S.M.;
J. Invest. Dermatol. 99:138-145(1992)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 110-417; VARIANT MET-171;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.